The Impartial Residents Oversight Committee of the California Institute for Regenerative Medication (CIRM) unanimously accredited yesterday two grants price a complete of virtually $Eight million to College of California San Diego College of Medication researchers investigating novel stem cell-based therapies for acute myeloid leukemia or AML.
In 2017, there shall be greater than 62,000 new circumstances of leukemia (of every kind) within the U.S. and 24,500 deaths, in keeping with the American Most cancers Society. AML will account for about one-third of latest leukemia circumstances and nearly half of all leukemia-related deaths. AML primarily afflicts adults, with a median affected person age of 67. It’s unusual earlier than the age of 45. Normal chemotherapy is efficient in two out of three AML sufferers, however a lot much less so for older sufferers, and recurrence is frequent.
The primary grant for $5.15 million was awarded to Dan Kaufman, MD, PhD, professor of drugs within the Division of Regenerative Medication, to advance medical translation of pure killer (NK) cells derived from human embryonic stem cells right into a standardized therapy for treating, and presumably curing, AML and different leukemias. NK cells are a sort of immune system cell vital to speedy response to infections and tumor formation. They get their identify from the flexibility to assault tumor cells with out requiring patient-specific triggering markers.
The second grant for $2.7 million was awarded to Catriona Jamieson, MD, PhD, deputy director of the Sanford Stem Cell Medical Heart and director of stem cell analysis at UC San Diego Moores Most cancers Heart, in collaboration with Michael Burkart, PhD, professor within the UC San Diego Division of Chemistry and Biochemistry, and Leslie Crews, PhD, assistant professor within the Division of Regenerative Medication at UC San Diego College of Medication. The funding will help testing of a novel therapeutic splicing modulator strategy concentrating on most cancers stem cells in AML. These cells, which evade or grow to be proof against most cancers therapy, are believed to be the reason for the excessive relapse fee in AML and different cancers.
“This analysis is critically necessary in advancing our information of stem cells and are the inspiration for future therapeutic candidates and coverings,” mentioned Maria Millan, MD, president and CEO of CIRM. “Exploring and testing new concepts will increase the probabilities of discovering therapies for sufferers with unmet medical wants. With out CIRM’s help, many of those initiatives would possibly by no means get off the bottom. That is why our means to fund analysis, significantly on the earliest stage, is so necessary to the sector as a complete.”